US protection ending in 2037
As of the edition of 20 October 2026, 29 drugs have US protection that ends in 2037; 17 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
29 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Baloxavir marboxil | Ends 2037 (patent) | Marketed | Roche | 0 | |
| Berahyaluronidase alfa | Ends 2037 (computed from the first US licence) | Marketed | Merck & Co. | 0 | |
| Clesrovimab | Ends 2037 (computed from the first US licence) | Marketed | Merck & Co. | 0 | |
| Datopotamab deruxtecan | Ends 2037 (computed from the first US licence) | Marketed | Daiichi Sankyo | TACSTD2, TOP1 | 2 |
| Depemokimab | Ends 2037 (computed from the first US licence) | Marketed | GSK | IL5 | 0 |
| Ensartinib | Ends 2037 (patent) | Marketed | Xcovery | ALK | 1 |
| Entrectinib | Ends 2037 (patent) | Marketed | Roche | ALK, NTRK1, NTRK2 | 4 |
| Eravacycline | Ends 2037 (patent) | Marketed | L | 0 | |
| Indigotindisulfonate | Ends 2037 (patent) | Marketed | Provepharm | 0 | |
| Lasmiditan | Ends 2037 (patent) | Marketed | Eli Lilly | HTR1F | 1 |
| Lerodalcibep | Ends 2037 (computed from the first US licence) | Marketed | LIB Therapeutics | PCSK9 | 1 |
| Linvoseltamab | Ends 2037 (computed from the first US licence) | Marketed | Regeneron | CD3D, CD3E, CD3G | 1 |
| Narsoplimab | Ends 2037 (computed from the first US licence) | Marketed | Omeros | MASP2 | 1 |
| Navepegritide | Ends 2037 (patent) | Marketed | Ascendis Pharma A/S | NPR2 | 1 |
| Nipocalimab | Ends 2037 (computed from the first US licence) | Marketed | Johnson & Johnson | FCGRT | 1 |
| Orforglipron | Ends 2037 (patent) | Marketed | Eli Lilly | GLP1R | 0 |
| Palopegteriparatide | Ends 2037 (patent) | Marketed | Ascendis Pharma A/S | PTH1R | 3 |
| Penpulimab | Ends 2037 (computed from the first US licence) | Marketed | Akeso | PDCD1 | 1 |
| Piflufolastat | Ends 2037 (patent) | Marketed | Lantheus Biosciences | FOLH1 | 2 |
| Prademagene zamikeracel | Ends 2037 (computed from the first US licence) | Marketed | Abeona Therapeutics | 0 | |
| Revakinagene taroretcel | Ends 2037 (reference-product exclusivity) | Marketed | Neurotech Pharmaceuticals | 0 | |
| Revumenib | Ends 2037 (patent) | Marketed | Syndax Pharmaceuticals | KMT2A, MEN1 | 1 |
| Sars-cov-2 virus spike protein | Ends 2037 (computed from the first US licence) | Marketed | Sanofi | 0 | |
| Sebetralstat | Ends 2037 (patent) | Marketed | Chiesi Farmaceutici | KLKB1 | 1 |
| Sibeprenlimab | Ends 2037 (computed from the first US licence) | Marketed | Otsuka | TNFSF13 | 1 |
| Telisotuzumab vedotin | Ends 2037 (computed from the first US licence) | Marketed | AbbVie | MET, TUBB, TUBB1 | 10 |
| Zanubrutinib | Ends 2037 (patent) | Marketed | BeiGene | BTK | 1 |
| Zopapogene imadenovec | Ends 2037 (computed from the first US licence) | Marketed | Precigen | 0 | |
| Zuranolone | Ends 2037 (patent) | Marketed | Biogen | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2037
In the product17 of these 29 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.